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The European Society of Cardiology (ESC) guidelines for management of atrial fibrillation (AF) recommend the use of CHA2DS2VASc risk
score for assessment of thromboembolic (TE) risk, whereas the stratification of bleeding risk should be obtained by HAS-Bleed to balance
the most appropriate anticoagulation (OAC) therapy. However, men with CHA2DS2VASc score = 1 and women with CHA2DS2VASc = 2,
who are at intermediate TE risk, represent a grey zone where guidelines do not provide a definite OAC indication. Accordingly, implementa-
tion of risk stratification with echocardiography could be extremely useful. Both prospective and cross-sectional studies on transthoracic
echocardiography (TTE) prediction of TE events and studies utilizing transoesophageal echocardiographic parameters as surrogate markers of
TE events makes sustainable the hypothesis that echocardiography could improve TE prediction in non-valvular AF. Moreover, considering
the close association of AF and stroke, all echo-Doppler parameters that have shown to predict AF onset and recurrence could be useful
also to predict TE events in this clinical setting. Accordingly, EACVI AFib Echo Europe Registry has been designed as an observational, cross-
sectional study, with the aim of evaluating: (i) left atrial (LA) size and function together with left ventricular geometry, systolic and diastolic
functions in paroxysmal, persistent, and permanent AF; (ii) relationships of structural/functional parameters with clinical TE and bleeding risk
profile. By the AFib Echo Europe Registry, we expect to collect data on echocardiographic phenotype of patients with AF. The large data set
accumulated will be useful to test the level of agreement of different echocardiographic measurements with the available risk scores.
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..Introduction
Atrial fibrillation (AF) is associated with a five-fold increased risk of
developing ischaemic stroke, and 20–30% of all ischaemic strokes are
directly related to AF.1,2 Oral anticoagulation (OAC) is able to
reduce mortality due to ischaemic stroke in AF,3 but the protective
effect against thromboembolic (TE) events needs to be balanced
with the bleeding risk induced by these drugs. The most recent guide-
lines recommend the use of CHA2DS2VASc risk score for assess-
ment of TE risk (both cerebral and peripheral) and establishing the
OAC need in non-valvular AF. Stratification of bleeding risk should
also be obtained, with the aim of identifying high-risk patients and
eliminate modifiable risk factors.4 However, a grey zone exists
for men with CHA2DS2VASc score = 1 and women with
CHA2DS2VASc = 2, who are at intermediate TE risk. Guidelines do
not provide a strong indication for OAC in these two categories, sug-
gesting that the choice should be individualized and based on patient’s
preference. Nevertheless, TE risk is not negligible in this grey zone,
with an event rate per year estimated to be up to 2.8% according to
case series.5–7 This setting of patients represents an even more deli-
cate population if they also present a high bleeding risk. In the
absence of strong guideline indications, the use of OAC can expose
these patients to haemorrhagic complications while its denial induces
avoidable TE events.
The implementation of clinical risk stratification with other tools
could be therefore extremely useful. Despite considered as an
extremely valuable technique for AF in a recent EACVI Expert
Consensus document,8 no definite indication exists in the current
guidelines about the use of echocardiographic parameters for esti-
mating TE risk in AF patients.
Studies on transthoracic
echocardiography prediction of
TE events
(1) Prospective studies. The most relevant studies testing the predictive
value of echocardiography in terms of incidence of TE events, inde-
pendent on clinical risk profile, are summarized in Table 1. Several
factors such as differences in inclusion criteria, choice of parameters
to be tested, and clinical risk factors considered as covariates could
have contributed to the heterogeneity of results obtained. Left atrial
(LA) dilatation emerged as an independent predictor of TE events
in non-valvular AF patients not undergoing OAC/antiplatelets
drugs9 and after surgical maze procedure for sinus rhythm restora-
tion.10 LA dilatation was an independent predictor of stroke recur-
rence in AF patients admitted to the hospital for acute ischaemic
stroke.11 Left ventricular (LV) systolic dysfunction was also a predic-
tor of thromboembolism in non-valvular AF case series.9,12
However, two prospective studies were not able to demonstrate
an independent predictive value against TE events in any of the ana-
lysed echo parameters in non-valvular AF.13,14 Worthy of note,
none of these prospective studies focused patients at intermediate
TE risk derived by clinical risk scores.
(2) Cross-sectional studies. A series of cross-sectional studies sought
to identify which echocardiographic parameter could be associated
with history of TE events in AF patients (Table 2). E/e0 ratio of mitral
annulus had an independent association with history of stroke both
in paroxysmal15 and permanent/persistent non-valvular AF.16 LA
peak systolic longitudinal strain was independently associated with
history of stroke in two series of non-valvular AF patients.17,18
(3) Transthoracic echocardiography and surrogate markers of TE
events. Some studies highlighted the predictive value of transoeso-
phageal echocardiography (TOE) derived LA cavity and appendage
(LAA) abnormalities—such as evidence of thrombi, dense sponta-
neous echo contrast (SEC), and low-flow velocities (LAA-LF)—in
relation with TE events.20–22 Accordingly, TOE parameters have
been utilized as surrogate markers of TE events (Table 3). In particu-
lar, LA dilatation predicted LAA thrombi, SEC and LF, independent
of CHADS2 and CHA2DS2VASc.
23,24 In a study on 376 non-valvular
AF patients, the addition of LA area (1 point if 24–32.5 cm2, 2 points
if > 32.5 cm2) and LV systolic function [1 point if LV ejection fraction
(EF) 45–54%, 2 if < 45%) to both CHADS2 and CHA2DS2VASc
improved their accuracy in predicting LAA thrombi, LF, and SEC.25
Also LV mass index was found to predict independently LA thrombi
formation.26
Rationale for an echo laboratory
registry
A lack of definitive data on the power of transthoracic echocardiog-
raphy in predicting TE events of AF patients remains evident mainly
because of the small sample size of the populations assessed.
Inhomogeneity of inclusion criteria and covariates, as well as unclear
definition of endpoints, limits also the possibility of performing meta-
analyses on the existing data. However, some measurements emerge
by the above-mentioned studies, in particular taking into account
their pathophysiologic meaning in relation with AF development and
maintenance. By considering the close association of AF and stroke,
all echo-Doppler parameters that have shown to predict AF onset
and recurrence could be useful also to predict TE events in this clini-
cal setting.
LA size represents per se a main determinant of AF new onset27–30
and recurrence.31–33 In 881 hypertensive patients with electrocardio-
gram (ECG)-derived LV hypertrophy (LVH) of the LIFE Study, a
greater LA diameter reduction during interventional follow-up was
associated with the absence of new-onset AF.34 In the Framingham
Heart Study, for every 10 mm increase in LA diameter, the relative
risk of stroke was 2.4 in men [95% confidence interval (CI) 1.6–3.7]
and 1.4 in women (95% CI 0.9–2.1), even after adjusting for ECG-
derived LV mass index.35 Some authors have recently proposed to
incorporate LA size in the stroke risk scoring, for a better risk assess-
ment and management of non-valvular AF.36 Additional information
could be gained by LA strain, which was found to predict new-onset
AF in different clinical settings.37–39
LV diastolic dysfunction and chronic increase of LV filling pressure
(LVFP) represent triggers for AF onset, recurrence and permanence.
E/e0 ratio predicted the development of AF independent on LA dila-
tion among elderly patients40 and was higher in patients with early
onset of AF following cardiac valve surgery.41 The rate of paroxysmal
AF increased exponentially with severity of LV diastolic dysfunction
after cardiac surgery.42 In 1169 patients with acute myocardial
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Table 1 Prospective studies assessing the predictive value of echocardiographic parameters vs. ischaemic stroke/sys-
temic thromboembolism
No. of
patients
Patients enrolled Endpoint Echo parame-
ters tested
Median
follow-up
No. of
events
Results
Gupta
et al.14
971 Non-valvular AF,
CHADS2 >_2,
anticoagulation
with edoxaban or
warfarin
Thromboembolic
events, death
for any cause
LV EF, LVMi, LV
EDVi, LAD,
LAVi, LA EF,
E/e0
2.5 years 48 No echo parameter
significantly predicted
the endpoint
Buber
et al.10
150 AF patients
undergoing maze
surgical procedure.
Anticoagulation
suspended3months
after procedure
Thromboembolic
stroke
LAVi, absence of
A wave at trans-
mitral PW
Doppler
17 months if A
wave present,
19 months if A
velocity absent
15 Absence of A wave pre-
dicts the endpoint in
the entire population
(HR 4.76; 95% CI
1.19–19.0, P= 0.02)
and in patients not on
anticoagulant (HR
4.18; 95% CI 1.07–
16.3, P= 0.04), LAVi
predicts the endpoint
in the entire popula-
tion (HR = 3.23; 95%
CI 1.10–9.48, P= 0.03)
but not in patients not
on anticoagulation
Ezekowitz
et al.12
1066 Non-valvular AF
patients
Ischaemic stroke LAD, LV septal
and posterior
wall thickness,
LVMi, LV dys-
function, MR,
MV prolapse
1.6 years 78 Only LV moderate–
severe systolic dys-
function is significantly
associated with the
endpoint at multivari-
ate analysis (RR 2.5;
95% CI 1.5–4.4,
P< 0.010)
Olshansky
et al.13
2474 Non-valvular AF
patients after
restoration of sinus
rhythm
Ischaemic stroke LAD, reduced LV
EF, MR at least
moderate
>5 years 86 No echo parameters sig-
nificantly associated
with the endpoint at
multivariate analysis
Paciaroni
et al.11
854 AF patients admitted
for acute ischaemic
stroke
Recurrence of
stroke/TIA,
systemic
embolism
LA enlargement
(LAD or LAVi)a
90 days 63 Severe atrial enlargement
predicts the endpoint
at multivariate analysis
(OR 2.05; 95% CI
1.08–2.87, P= 0.027)
Asinger
et al.9
568 Non-valvular AF
patients not on
anticoagulant or
antiplatelet
Ischaemic
stroke/systemic
embolism
LAD index, LVMi,
LV EDD and
ESD, FS, LV
systolic dysfunc-
tion, severe MR
1.3 years 46 LV dysfunction (RR = 2.0;
95% CI 1.0–4.0,
P< 0.05) and LAD
(RR = 1.6; 95% CI 1.0–
2.5, P= 0.04) are inde-
pendent predictors of
the endpoint
AF, atrial fibrillation; EDD, end-diastolic diameter; EDVi, end-diastolic volume index; EF, ejection fraction; ESD, end-systolic diameter; FS, fractional shortening; LA, left atrium;
LAD, left atrial anteroposterior diameter; LAVi, left atrial volume index; LV , left ventricular; LVMi, LV mass index; MR, mitral regurgitation; MV, mitral valve.
aFor LAD: mild dilatation = 39–42 mm in female/41–46 mm in male; moderate dilatation = 43–46 mm in female/47–52 mm in male; severe dilatation >46 in female/>52 in male.
For LAVi: mild dilatation = 29–33 mL/m2; moderate dilatation = 34–39 mL/m2; severe dilatation <39 mL/m2.
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..infarction, the risk of new-onset AF was higher in patients with
restrictive filling pattern.43
LV hypertrophy (LVH) is a recognized predictor of AF because it
induces diastolic dysfunction, LVFP increase, and subsequent LA dila-
tion. In the large population of ARAPACIS Study, patients with non-
valvular AF and clear-cut LVH showed higher TE risk.44 In a recent
meta-analysis, patients with LVH had three- to four-fold greater odds
of developing supraventricular arrhythmias including AF.45 In a
restrospective analysis of 171 patients with cryptogenic ischaemic
attacks, echocardiographic LVH independently predicted AF
detected by Holter ECG.46 In the elderly cohort of the Framingham
Study, the hazard ratio (HR) for cerebrovascular events comparing
highest to lowest quartile of LV mass index was 2.72 (95% CI 1.39–
5.36), after adjusting for several confounders.47
The association of LV systolic dysfunction with AF and TE events is
so obvious that LV EF < 40% (as alternative of symptoms/signs of
heart failure) is one of the components of CHA2DS2VASc risk score.
A vicious circle exists between AF and heart failure and AF predicted
new-onset heart failure with preserved EF but not with reduced EF in
the Framingham Study.48 Early impairment of LV global longitudinal
strain was associated with an increased risk of incident AF in diabetic
patients49 and after acute myocardial infarction.50
According to these findings, it is conceivable that the integration of
one or more echo Doppler parameter with the available clinical
scores could substantially improve TE risk prediction in patients at
intermediate risk according to CHA2DS2VASc (CHA2DS2VASc
classes 1 if males and 2 if females). Also patients undergoing catheter
ablation could benefit from this approach. In this setting of patients,
guidelines recommend prosecution of OAC if at high risk, regardless
of the success of the procedure, without any definite evidence.
Indeed, the German Ablation Registry identified hypertensive heart
disease (LVH, LV diastolic or systolic dysfunction) as an independent
predictor of periprocedural ischaemic stroke.51
Figure 1 illustrates the key parameters that could be incorporated
in TE predicting scores. Among these parameters, left atrial volume
index (LAVi)52 and E/e0 ratio53 have the advantage of being more
reproducible than LV mass and LV EF54,55 and could be therefore
particularly promoted.
....................................................................................................................................................................................................................
Table 2 Cross-sectional studies assessing the association of echocardiographic parameters with prevalence of ischae-
mic stroke/systemic thromboembolism
No. of
patients
Patients enrolled Event
assessed
Echo parameters
tested
No. of
events
Results
Kim et al.15 1098 Paroxysmal non valvular AF
patients undergoing
catheter ablation
Stroke/TIA LAD, LVMi, LV EF,
transmitral E veloc-
ity, e0 velocity, s0
velocity, E/e0
114 LAD, e0 velocity, s0 velocity and
E/e0 associated with stroke/
TIA at univariate analyses
Only E/e0 associated with
stroke/TIA at multivariate
analysis after controlling for
clinical risk factors
Lee et al.16 330 Permanent/persistent AF,
LV EF > 40%, absence of
severe valve disease,
congenital heart disease or
hypertrophic
cardiomyopathy
Stroke LAVi, E velocity, e0
velocity, E/e0
50 E velocity, e0 velocity and E/e0
associated with stroke at uni-
variate analysis. At multivari-
ate regression analysis only E/
e0 (odds ratio = 1.21,
P= 0.002) associated with
stroke
Obokata et al.17 285 Non valvular AF patients
admitted for acute stroke/
embolism (N= 82) and AF
control patients without
stroke (n= 203)
Stroke/
embolism
LAVi (max), LAVi
(min), LA emptying
fraction, LA strain
82 LA strain independently associ-
ated with stroke/embolism at
multivariate analysis
Sakabe et al.19 76 Paroxysmal non-valvular AF
with no risk factors or only
mild hypertension
Stroke E/A ratio, atrial
reverse velocity,
LAV
26 E/A ratio (>_1.00), AR velocity
(<_25 cm/s), and LA volume
(>_107 mL) are significantly
associated with stroke
Shih et al.18 79 Permanent non valvular AF
patients
Stroke LA peak strain and LA
strain rate during
reservoir and con-
duct, e0 velocity,
E/e0 .
20 LA peak strain and strain rate
during reservoir are inde-
pendently associated with
stroke at multivariate analysis
Abbreviations as in Table 1.
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Table 3 Studies assessing the association of echocardiographic parameters with surrogate markers of ischaemic
stroke/systemic thromboembolic risk
No. of
patients
Patients enrolled Endpoint Echo parameters
tested
Results
Doukky et al.24 297 Non valvular AF undergoing TOE
and TTE (within 1 year)
LAA thrombus at
TOE
LAVi, e0 velocity,
E/e0 LV EF
LAVi, e0 velocity and E/e0 are inde-
pendently associated with the
endpoint at multivariate analysis
Faustino et al.23 500 AF patients undergoing TTE and
TOE before cardioversion
LAA thrombus, low
LAA velocity, LAA
spontaneous echo
contrast (SEC)
LAD, LAVi, LA area
four-chamber index
LAVi and LA area four-chamber
index are independently associ-
ated with the endpoints.
Boyd et al.26 165 AF patients undergoing TTE and
TOE before cardioversion
LAA thrombus LVMi, e0 velocity
(TTE), LAA empty-
ing velocity, LA and
RA SEC (TOE)
LVMi independent predictor of the
endpoint at multivariate analysis
Provideˆncia et al.25 376 Non-valvular AF patients under-
going TOE and TTE
LAA thrombus, low
LAA velocity,
LAASEC
LAD, LA area, LV EF Adding LA area and LV global sys-
tolic function to CHADS2 and
CHA2DS2VASc scores resulted in
an improvement of AUC for the
prediction of the different
endpoints
Abbreviations as in Table 1.
Figure 1 Key echo-Doppler parameters of potential additive value for thromboembolic risk prediction. LA, left atrial; LAd, left atrial diameter;
LAVi, left atrial volume index; LV, left ventricular.
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Design of the EACVI AFib Echo
Europe Registry
EACVI AFib Echo Europe Registry has been designed as an observa-
tional, cross-sectional study, with the aim of evaluating the relation-
ship of echocardiographic parameters of LA dimension and function,
LV geometry, LV systolic and diastolic function with clinical TE and
bleeding risk profile as assessed using CHA2DS2VASc and HASBLED
scores.
Secondary objectives of the registry will be:
(1) To evaluate the echocardiographic phenotype of patients with par-
oxysmal, persistent and permanent AF;
(2) To evaluate the echocardiographic phenotype of patients at inter-
mediate TE risk (CHA2DS2VASc = 1 in men or 2 if women).
The AFib Echo Europe Registry will be a multicentre registry involv-
ing 20 reference European echocardiographic laboratories, chosen
among the accredited echo labs under the guidance of European
National Societies and Working Groups, along a period of 6 months.
Protocol of AFib Echo Europe
Registry
All consecutive patients with non-valvular permanent, persistent or
paroxysmal AF having a heart rate between 60 and 100 bpm under-
going a transthoracic echocardiographic examination will be
recruited in the echo labs participating the Registry during the period
of 6 months. Informed consent to the enrolment in the study will be
obtained. Exclusion criteria will be previous catheter or surgical abla-
tion, LAA occlusion, cardiac surgery or percutaneous non-coronary
interventional procedures, moderate-to-severe mitral and aortic
valve stenosis, severe mitral and aortic valve regurgitation, mitral and
aortic prosthesis, sepsis and poor acoustic window.
Anthropometric parameters (age, gender, height, and weight),
blood pressure, and heart rate will be recorded. A detailed medical
history and physical examination will be obtained and data included.
Components of CHA2DS2VASC and HAS-BLED scores will be eval-
uated and recorded. Data on cardiac therapy including also OAC will
be also collected.
Scores
CHA2DS2VASc and HAS-BLED scores will be determined after col-
lecting anamnestic and demographic data on individual patients,
according to standardized procedures.56,57
Doppler echo parameters
2D, colour, and Doppler echocardiography will include evaluation
and recording of the following parameters:
• ‘LV geometry and systolic function’, according to the European
Association of Cardiovascular Imaging (EACVI)/American Society
of Echocardiography (ASE) recommendations for chamber quanti-
fication58: LV end-diastolic and end-systolic diameters, LV mass
index and relative wall thickness, LV end-diastolic, LV end-systolic
volumes and EF (Simpson biplane), LV global longitudinal strain
(GLS) using 2D speckle-tracking echocardiography.
• ‘LV diastolic function’, according to the ASE/EACVI recommenda-
tions59: pulsed Doppler transmitral inflow pattern parameters:
peak E velocity, A velocity, E/A ratio and E velocity deceleration
time, pulsed tissue Doppler measurements of septal and lateral
mitral annulus with measurement of average (between septal and
lateral) e0 velocity, a0 velocity and s0 velocity, and E/e0 ratio.
Pulmonary arterial systolic pressure will be estimated from maxi-
mal gradient of tricuspid regurgitation (if present) þ estimation of
right atrial pressure by quantitation of inferior vena cava size and
respiratory collapse.
• ‘LA evaluation’59,60: LA anteroposterior diameter of LA, LA vol-
ume (biplane area–length method) index, LA emptying index (by
subtracting LA end-diastolic volume from LA end-systolic volume),
and LA ejection fraction [(LAEF = LA end-diastolic volume - LA
end-systolic volume)/LA end-diastolic volume 100], LA expan-
sion index (LAFI = LAEFLVOT-VTI/LAESVI, where LVOT-VTI is
velocity time index of LV outflow tract and LAESVI is LA end-
systolic volume index), LA peak longitudinal systolic strain (PALS)
using speckle-tracking echocardiography, averaged between four-
chamber and two-chamber apical views (optional parameter), will
be determined.
All the reported echo-Doppler measurements will be averaged
from three cardiac cycles in patients in sinus rhythm and from five
cardiac cycles during AF.
In addition, evidence and degree of mitral, aortic, and tricuspid
stenosis/regurgitation will be reported according to the most recent
EACVI recommendation.61,62 Among the enrolled patients, those
with a clinical indication for TOE will undergo evaluation of LAA
appendage: evidence of LAA thrombi, dense spontaneous echo con-
trast, and LAA velocities measurement with pulsed-wave Doppler
(average of inwards and outwards velocities from three cardiac cycles
in patients in sinus rhythm and from five cardiac cycles during AF) will
be recorded by this technique.
Quality control
Each peripheral echocardiography laboratory will follow the standard
operational procedures recommended by the principal investigator
(PI) and the steering committee.
A brief tutorial will be created to explain how to perform all the
measures required for the registry in a standardized manner, in agree-
ment with the most recent EACVI recommendations.58–62
The PI will plan to ensure the quality control of echocardiograms
performed in peripheral echocardiographic laboratories and optimize
reading procedures to limit the inter- and intra-observer variability of
measurements. The reproducibility among the laboratories involved
will be checked (Bland and Altman test; interclass correlation coeffi-
cient, inter-rater agreement: Kappa) on a data set of 15 echocardio-
graphic examinations provided by the PI and the steering committee.
Continuous connections will be kept between both PI and steering
committee during overall registry duration period.
Ethical committee
The AFib Echo Europe Registry will be developed according to the
common rules for research in human subjects. Privacy protection
with regard to processing of individual data will be ensured.
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The ethical committees of the Institutions involved will approve the
project. All patients will have to give their written informed consent.
The sample size
According to the previous results derived from a preliminary registry
data collected in the Echo Laboratory of Federico II University
Hospital, Naples, Italy (n= 200), the expected standard deviation for
indexed LA volume and LA strain would be 15.6 mL/m2 and 10.9%,
respectively. Using a CI at 95% and a margin at 2.5%, a sample size of
1000 patients would be acceptable. In addition, this sample size will
be able to appropriately answer to the secondary objective of the
study with high statistical power. This sample size will also allow fur-
ther statistical multivariate adjustment aiming to identify whether LA
parameters are independent determinants of CHA2DS2VASc score.
However, missing data can be expected and their management
should be planned. In this regard, 17% of LA strain was not available,
requiring us to increase the sample size to 1204 patients.
Expectations of the registry
We expect to collect data on the echocardiographic phenotype of
patients with any kind of AF in a panorama of reference European
echo labs involved in the Registry. The large data set we expect to
accumulate will be in particular useful to test the level of agreement
of different echocardiographic measurements with the available TE
and bleeding risk scores. It is expected that the additional usefulness
of echocardiographic examination could emerge to create future
projects for stratifying prognosis and improving management in cate-
gories of AF patients.
Steering committee of EACVI
AFib Echo Registry
Maurizio Galderisi (PI, Chair), Erwan Donal (Vice Chair), Julien
Magne (responsible for data management and statistical analyses),
Francesco Lo Iudice, Eustachio Agricola, Leyla Elif Sade, Matteo
Cameli, Ehud Schwammenthal, Nuno Cardim, Bernard Cosyns,
Andreas Hagendorff, Alexander N. Neskovic, Jose` Luis Zamorano,
Patrizio Lancellotti, Gilbert Habib, Thor Edvardsen, and Bogdan A.
Popescu.
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